Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Court Says "No" To Linking Patents With Regulatory Approvals; Sends Back Six Patent Oppositions

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In two back-to-back judgments delivered by the Delhi High Court this week, multinational drug companies Bayer and Eli Lilly suffered major setbacks as the Indian court rejected their separate pleas - one related to the linkage of patent grants with regulatory approvals and the other a re-examination of the existing system for patent oppositions

You may also be interested in...



India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie

MUMBAI - Cipla - India's largest drug maker by market share - will not be amongst the first bunch of companies that prepare to launch biosimilars in the U.S

India's Cipla Not Ready For U.S. Biosimilars Market Even As Peers Line Up For Bigger Piece Of Pie

MUMBAI - Cipla - India's largest drug maker by market share - will not be amongst the first bunch of companies that prepare to launch biosimilars in the U.S

Indian Court Nixes Bayer's Nexavar Patent Plea; Cipla Allowed To Market Generic Versions

MUMBAI - In a landmark decision that will further restrict multinational drug companies from introducing their internationally marketed brands in India, the Delhi High Court rejected German drug maker Bayer's plea to stop the Drug Controller General of India - the Indian drug regulator - from granting marketing approval to generic drug maker Cipla for kidney/liver cancer drug Nexavar (sorafenib)

Related Content

UsernamePublicRestriction

Register

SC073987

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel